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Summary Nasal continuous positive airway pressure (nCPAP) has been widely
established in the treatment of obstructive sleep apnea syndrome (OSAS). However,
only few studies have evaluated long-term effects of this treatment on lung function.
This study assesses the effect of nCPAP on lung function parameters and response to
bronchodilators in 50 OSAS patients. Spirometry and arterial blood gas measurements
were performed before starting nCPAP and after 16.878 months of treatment. Of the
50 study patients (55712 years, with an apnea/hypopnea index of 47734 h1), 15
had asthma, 13 had chronic obstructive pulmonary disease (COPD) and 22 had no
obstructive airway disease (NOAD). In the entire population, significant decreases in
FEF50 (from 69738% to 61730%, Po0:005), FEF25 (from 53734% to 46728%, Po0:05)
and FEF2575 (from 65733% to 57727%, Po0:005) were observed after treatment. No
impairment of lung function was found in COPD and asthmatic patients. In contrast,
lung function was changed in the NOAD group where FEF50, FEF25 and FEF2575 as well
as FEV1 and FEV1/VC ratio were significantly reduced. Moreover, bronchial
hyperresponsiveness occurred in five of 22 patients of this group. These results
suggest that tolerance of nCPAP should be handled by long-term follow-up of flow-
volume loops.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
Obstructive sleep apnea syndrome (OSAS) repre-
sents an important health problem because of a
prevalence of at least 1–4%,1 frequent association
with obesity,2 systemic hypertension3 and in-
creased mortality without treatment.4,5 Since the
first publication in 1981,6 nasal continuous positive
airway pressure (nCPAP) has been widely estab-
lished in the treatment of OSAS. However, only few
studies have evaluated long-term effects of this
treatment on lung function.7–9 In patients with
chronic obstructive pulmonary disease (COPD),
both positive end-expiratory pressure and CPAP
have been shown to reduce the work of breathing
by minimizing dynamic airway collapse during
expiration.10–12 In asthmatic subjects in whom
bronchospasm was induced by histamine, CPAP is
thought to reduce pulmonary resistance and in-
spiratory muscles work.13 More recently, nCPAP was
shown to improve bronchial smooth muscle hyper-
reactivity to methacholine.14 However, the effec-
tiveness of CPAP in asthma is still conflicting.
Interestingly, bronchial hyperreactivity to hista-
mine has been reported in some patients treated by
nCPAP for OSAS,15 but no other adverse effect of
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long-term nCPAP on lung function has been
described.
The aim of this study was to assess the effect of
nCPAP on lung function parameters and airway
responsiveness (response to bronchodilators) in 50
OSAS patients with or without obstructive spiro-
graphic pattern.
Methods
Patient selection
Two hundred patients with sleep respiratory dis-
orders have been screened in our center for a 4-
year period. Among them, 50 patients were
included in this study. All these patients gave
informed consent. The inclusion criteria were an
apnea/hypopnea index (AHI) of more than 10 per
hour at baseline, the normalization of the AHI
(i.e. AHIo10) and the disappearance or a clear
improvement of the related symptoms (snoring,
excessive daytime sleepiness) resulting of nCPAP
use and the acceptance of home nocturnal nCPAP.
Study protocol
All patients underwent two full polysomnographies,
performed at baseline without nCPAP and with
nCPAP. Polysomnography included electroencepha-
lography (C4-A1, C3-A2, T4-O2), electrooculogra-
phy, chinelectromyography, electrocardiography,
nasal flow and oxygen saturation monitored via a
finger probe. Neurophysiological and ventilatory
signals were recorded using a CID 108-102 device
(CIDELEC, Angers, France).
Patients were health screened at entry with
uniform medical history and physical examination
along with blood gases, spirometry, chest radio-
graphy and electrocardiography.
Spirometry (including bronchodilator testing) and
arterial blood gas measurements were performed
before starting nCPAP and after 1778 months of
treatment.
Spirometry measurements and flow-volume
curves were obtained using a body plethysmograph
(PF/DX 1085D; MedGraphics, St. Paul, MN) with a
heated pneumotachometer for flow measurement.
The highest values of three technically satisfactory
forced expirations were used. The spirometry
technique met international standards and refer-
ences values were those of the European Respira-
tory Society.16 Results are expressed as absolute
volumes (ml) and as percentages of predicted
values (% pred).
Bronchial hyperresponsiveness was defined by an
increase of FEV1 of 200ml and more than 12% or an
increase of FEF25, FEF50 and FEF2575 of more than
50% (without change in VC) after inhalation of
200 mg Salbutamol.
Arterial blood was drawn from the radial artery
with the patient awake and semi-supine. The blood
sample was analyzed for pH, pCO2 and pO2 (1306 IL;
Paris, France).
In view of the presence of patients with
obstructive airway disease, three groups were
defined: those with an history or clinical evidence
of asthma, those with COPD defined by airway
obstruction [obstructive spirographic pattern with
FEV1/VC ratio (forced expiratory volume in one
second/vital capacity) o70%] and those without
obstructive airway disease (no obstructive airway
disease [NOAD]).
Statistics
Data were expressed as mean7SD. Comparisons of
the three groups according to the health status
were made using analysis of variance (ANOVA). We
also used the w2 test to compare the distribution of
smoking habits between the three groups. Baseline
and follow-up values were compared using Stu-
dent’s paired t-test. Non-parametric tests (Wilcox-
on rank sum and Mann–Whitney tests) were used for
small groups. Values were different with signifi-
cance set at the Po0:05 level.
Results
Patients characteristics
The 50 patients were 55712 years, with a body
mass index (BMI) of 3678 kgm2 and an AHI of
47734 h1. Baseline anthropometric, polysomno-
graphic and lung function data before nCPAP
treatment are summarized in Table 1. Of the 50
study patients, 15 had asthma, 13 had COPD and 22
were NOAD. Among all data, smoking habit, FEV1,
FEF50 (forced expiratory flow at 50% vital capacity),
FEF25 (forced expiratory flow at 25% vital capacity),
FEV1/VC, VC and PaO2 were significantly different
between NOAD and COPD or asthma (Po0:02).
FEF2575 (forced expiratory flow between 25% and
75% of the vital capacity) was significantly different
in the three groups (Po0:02).
Mean nCPAP level needed to treat patients was
8.972.3 cm H2O. The compliance to nCPAP treat-
ment, expressed by the cumulated time of using,
was 5.970.9 h/night.
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Lung function changes
In the entire study population of the 50 patients,
significant decreases in FEF50 (from 69738% to
61730%, Po0:005), FEF25 (from 53734% to
46728%, Po0:05) and FEF2575 (from 65733% to
57727%, Po0:005) were observed. A significant
increase in PaO2 and decrease in PaCO2 were seen
(respectively, from 73713 to 76711mmHg for
PaO2, Po0:01; and from 4375 to 4174mmHg for
PaCO2, Po0:01). However, BMI, FEV1/VC, FEV1, VC,
FRC (functional residual capacity), RV (residual
volume) and TLC (total lung capacity) [% pred and
ml] did not change significantly.
When health status was taken into account (Fig
1A), lung function was significantly worse in the
NOAD group. FEV1, FEF50, FEF25 (% pred and mL),
FEF2575 (% pred) and FEV1/VC ratio were signifi-
cantly reduced. Moreover, no statistical difference
was observed in PaO2 and PaCO2 before and after
follow-up in the NOAD group. In contrast, PaO2 was
improved in the asthma group (from 69717 to
7579mmHg, n ¼ 13; Po0:05) and in the COPD
group (from 67711 to 75713mmHg, Po0:005),
and PaCO2 was reduced in asthmatic patients (from
4576 to 4375mmHg, n ¼ 13; Po0:05).
Bronchial responsiveness
Bronchial hyperresponsiveness occurred in five of
22 patients of the NOAD group (Fig 1B). These five
patients were not smokers. Their age, BMI, AHI and
nCPAP level were not different from the NOAD
group. Their BMI was stable during the follow-up
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Table 1 Anthropometric, polysomnographic and lung function data before nCPAP treatment (mean7SD).
Asthma (n ¼ 15) COPD (n ¼ 13) NOAD (n ¼ 22) ANOVA or w2w
Age (year) 51711 56714 56712 NS
Sex (M/F) 8/7 9/4 16/6 NS
BMI
(kgm2)
3977 3778 3579 NS
Smokers
(n)
11/15 12/13 9/22 Po0:005
Smoking
history
(pack year)
28727 33721 9717 Po0:005
AHI (h1) 47727 35726 53742 NS
PaO2
(mmHg)
69716 67711 79710 Po0:05
PaCO2
(mmHg)
4476 4374 4175 NS
FEV1/VC
(%)
62714 66715 79710 Po0:005
FEV1 (%
pred)
64722 70724 98726 Po0:0001
FEF50 (%
pred)
42725 53729 96731 Po0:0001
FEF25 (%
pred)
28720 42720 77733 Po0:0001
FEF2575 (%
pred)
34719a 56725a 94721a Po0:0001
VC (% pred) 81716 83717 101721 Po0:005
FRC (%
pred)
95721 99724 92724 NS
TLC (%
pred)
93717 93712 97717 NS
RV (% pred) 121734 115732 102732 NS
NOAD: no obstructive airway disease, BMI: body mass index, AHI: apnea/hypopnea index. Lung function parameters are
expressed as the percentages of predicted values (% pred). FEV1/VC: forced expiratory volume in one second/vital capacity,
FEFx: forced expiratory flow at x% vital capacity, VC: vital capacity, FRC: functional residual capacity, TLC: total lung capacity
and RV: residual volume.
aValues were significantly different in the three groups (Po0:02).
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period and no difference in VC, FRC, RV and TLC (%
pred and ml) were observed. All had nCPAP with
humidification systems. Three of these five patients
had history of chronic rhinitis. One of these
patients, who developed a severe obstructive
spirographic pattern, needed bronchodilator and
corticosteroid treatment.
Discussion
The main result of the present study is that lung
function and bronchial responsiveness may be
impaired by long-term treatment of OSAS by nCPAP.
The impairment is observed only in patients with
normal initial lung function.
To our knowledge, this is the first study that
describes a decrease of forced expiratory flows
in NOAD patients treated by nCPAP for OSAS.
Chaouat et al.9 reported a significant decrease of
FEV1 after long-term nCPAP treatment (6476
months) related to high percentage of smokers
and ex-smokers (77%). In our study, the shorter
period of follow-up (1778 months) and the
lower percentage of smokers (64%) do not support
this hypothesis. Five cases of bronchial hyperre-
sponsiveness were observed among 22 NOAD
patients. Wenzel et al.15 reported cases of
bronchial hyperreactivity but after short-term
follow-up and in lower proportion. No case of
bronchial responsiveness like in our study was
described elsewhere.
One hypothesis for the occurrence of obstructive
spirographic pattern is that CPAP may irritate
airway epithelia and induce airway inflammation.
In animal models, prolonged exposure to high
intermittent positive pressure ventilation induces
airway remodeling and airway hyperreactivity as
tested in vitro with carbachol.17 Although level of
CPAP was low in our study, chronic exposure to
positive pressure ventilation might produce similar
effects in man. The second hypothesis is that long-
term nCPAP may act as a mechanical alteration of
the nasal mucosa and creates a change in small
airway resistance via a nasobronchial reflex.18 No
bronchoconstriction reflex after nasal histamine
or allergenic provocation has been observed in
patients with allergenic rhinitis associated with
asthma. However, increased airway hyperreactivity
after nasal allergenic provocation test is well
known.19,20 The role of proinflammatory mediators
secreted by nasal epithelial cells is also evoked.
These results suggest a link between upper airway
inflammation and bronchial airway hyperreactivity.
This hypothesis may explain our results in at
least three patients with chronic rhinitis history.
However, upper airway inflammatory disease was
not systematically evaluated in our study popula-
tion, and bronchial hyperreactivity was not
assessed.
For the entire population, no change in FEV1, VC,
FRC and TLC was observed. Although the 50
patients included in our study were similar to other
series of OSAS patients with regard to initial lung
function and arterial blood gases,7–9 differences in
long-term follow-up were seen. Young et al.8
reported a significant fall of TLC, FRC and RV after
1 year of nCPAP and suggested that this decrease of
lung volume was consistent with change in respira-
tory muscle tone of initially hyperinflated patients.
In our study, patients were not hyperinflated.
Finally, the decrease of FEF50, FEF25 and FEF2575
observed in our patients was not reported else-
where.
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Figure 1 (A) Lung function changes. Mean values (þ 2
SEM) of FEV1, FEV1/VC, FEF50, FEF25 FEF2575 before and
after nCPAP treatment in COPD, asthma and NOAD
patients. (B) Bronchial responsiveness observed in five
patients of the NOAD group. Mean values (þ 2 SEM) of
FEV1 and FEF2575 before nCPAP (pre-nCPAP), after nCPAP
(post-nCPAP) and before bronchodilator (pre-BD), after
nCPAP and after bronchodilator (post-BD). NOAD¼ no
obstructive airway disease group, FEV1/VC¼ forced ex-
piratory volume in one second/vital capacity,
FEFx¼ forced expiratory flow at x% vital capacity.
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Conclusions
This study shows that long-term nCPAP may modify
flow-volume loops of patients without initial
obstructive spirographic pattern. Prospective stu-
dies evaluating airway responsiveness to b2-ago-
nists and hyperreactivity to methacholine are
needed to further explore the pathophysiological
mechanisms involved. These results suggest that
tolerance of nCPAP should be controlled by long-
term follow-up of flow-volume loops and compared
to new protocols of treatment.
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